RecruitingPhase 3NCT02064673
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Randomized Trial of Adjuvant Curcumin After Prostatectomy
Sponsor
yair lotan
Enrollment
608 participants
Start Date
May 1, 2014
Study Type
INTERVENTIONAL
Conditions
Summary
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Eligibility
Sex: MALEMin Age: 30 YearsMax Age: 80 Years
Inclusion Criteria11
- Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
- pathologically confirmed T1-T3 disease
- no sign of lymph node or metastatic disease
- pT1-pT3pNxMx patients in whom standard NCCN or AUA guidelines would suggest are at low risk for pelvic lymph node or metastatic disease and who would not require confirmatory imaging for metastatic disease. This includes patients with Gleason 6 or 7(T2 disease) and PSA less than 20.
- Eastern Cooperative Oncology Group(ECOG) status 0-2
- adequate renal and liver function as well as bone marrow reserve (measured serum creatinine \<2mg/dl, bilirubin ≤ 1.5 mg/dl, ANC ≥ 1.5 x 10 (3) uL, platelets ≥ 50 x K/uLL, and hemoglobin ≥ 10 g/dL)
- y/o at time of diagnosis with a life expectancy of \>= 3 yrs
- focally positive surgical margins are permitted
- no plan to receive adjuvant hormone or radiation therapy
- PSA at the time of enrollment must be undetectable
- life expectancy of 3 years
Exclusion Criteria11
- must not have exceeded 3 months from time of surgery to enrollment into study
- T3b or T4 or node positive disease
- macroscopic residual disease after surgery
- hormone therapy before surgery
- history of gallbladder problems or gallstones, or biliary obstruction, unless patient had cholecystectomy
- radiation therapy as primary treatment after surgery
- INR value greater than 1.5
- AST/ALT are equal or greater than 2 times the upper limit of normal
- antiplatelet or anticoagulant agents- patients taking 81mg of Aspirin will be allowed with close observation
- history of gastric or duodenal ulcers or untreated hyperacidity syndromes
- patients who are currently taking curcumin and are unwilling to stop or plan to take curcumin during the study
Interventions
DRUGCurcumin
Curcumin or placebo 500mg by mouth twice a day for 6 months
DRUGplacebo
placebo orally twice a day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02064673
Related Trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT057519412 locations